(Q36163952)

12 August 2017

1 reference

title

Controversies in breast cancer: adjuvant and neoadjuvant therapy (English)

1 reference

12 August 2017

Filippo Montemurro

1

1 reference

12 August 2017

Stefania Redana

series ordinal

2

1 reference

12 August 2017

Giorgio Valabrega

series ordinal

3

1 reference

12 August 2017

Massimo Aglietta

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

1055-1072

1 reference

Dormancy of mammary carcinoma after mastectomy.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Mechanisms of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Anastrozole in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Exemestane and aromatase inhibitors in the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Primary systemic therapy in operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Trastuzumab-based combination therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1055

10.1517/14656566.6.7.1055

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference